Document Detail

Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience.
MedLine Citation:
PMID:  21724297     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate effectiveness and safety of adalimumab in CD patients of the Madrid area and identify predictors of response.
METHODS: Multicenter retrospective survey of all CD patients treated with adalimumab in 9 hospitals of the Madrid area (Spain). Univariate and multivariate analysis of predictors of response was performed.
RESULTS: 174 patients included (50% males) with a median follow-up of 40 weeks. 30% had active perianal fistulizing disease at the beginning of the therapy with adalimumab. 59% had been previously treated with infliximab, being the lost of response (42.2%) the most frequent cause of withdrawal of the drug. 33% of patients needed dose escalation from every-other week to every week. The median time for this dose escalation was 33 weeks (range 2-120). The percentages of complete response at 4 weeks, 6 months and end of follow-up were 63, 70 and 63% in luminal disease and 49, 50 and 41% in perianal disease respectively. The prevalence of adverse events was 18% (most frequent was: 5 abscesses) causing the withdrawal of the drug in 21% of them.
CONCLUSIONS: Adalimumab is effective and safe for the management of CD, even in refractory cases to infliximab.
José Ignacio Fortea-Ormaechea; Yago González-Lama; Begoña Casis; María Chaparro; Pilar López Serrano; Manuel Van Domselaar; Fernando Bermejo; Ramón Pajares; Angel Ponferrada; María Isabel Vera; Pilar Martínez Montiel; Javier P Gisbert; José Luis Pérez-Calle; Antonio López San Román; Luis Abreu; Luis Alberto Menchén; Ignacio Marín-Jiménez
Related Documents :
8791977 - Surgical treatment of the ulnar nerve entrapment neuropathy: submuscular anterior trans...
25463127 - Permanent polymer of drug eluting stents increases eosinophil cationic protein levels f...
25307257 - Overstuffing in total knee replacement: no effect on clinical outcomes or anterior knee...
25491157 - Contemporary outcomes of open repair of thoracoabdominal aortic aneurysm in young patie...
24518607 - Split-thickness skin grafting the high-risk diabetic foot.
20116207 - Radiofrequency-powered segmental thermal obliteration carried out with the closurefast ...
Publication Detail:
Type:  Journal Article; Multicenter Study     Date:  2011-07-02
Journal Detail:
Title:  Gastroenterología y hepatología     Volume:  34     ISSN:  0210-5705     ISO Abbreviation:  Gastroenterol Hepatol     Publication Date:    2011 Aug-Sep
Date Detail:
Created Date:  2011-08-08     Completed Date:  2012-01-05     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8406671     Medline TA:  Gastroenterol Hepatol     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  443-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier España, S.L. All rights reserved.
Digestive Disease Department, Hospital Gregorio Marañón, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abscess / chemically induced
Antibodies, Monoclonal, Humanized / administration & dosage,  adverse effects,  therapeutic use*
Azathioprine / administration & dosage,  therapeutic use
Combined Modality Therapy
Crohn Disease / complications,  drug therapy*,  pathology,  surgery
Cutaneous Fistula / drug therapy
Dose-Response Relationship, Drug
Drug Evaluation
Drug Therapy, Combination
Follow-Up Studies
Hospitals, Urban
Immunosuppressive Agents / administration & dosage,  adverse effects,  therapeutic use*
Rectal Fistula / drug therapy
Retrospective Studies
Smoking / adverse effects,  epidemiology
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Immunosuppressive Agents; 0/Tumor Necrosis Factor-alpha; 446-86-6/Azathioprine; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diagnostic testing for Clostridium difficile: a comprehensive survey of laboratories in England.
Next Document:  Dopaminergic agonists in Parkinson's disease.